India Steps Up Scrutiny After Chinese API Prices, Military Tensions Rise

Drug Shortages Not Expected In The Short-Term

A recent military skirmish with China and a 35-40% average increase in prices of drug raw materials has seen India step up scrutiny of imports from the country. While the industry is seeking a hike in domestic formulations prices, product shortages are not expected in the short term.

China and India flags
Political Posturing Or Business Troubles? • Source: Shutterstock

India’s customs department recently stepped up its scrutiny of pharmaceutical raw materials imported from China after several, including those for drugs such as paracetamol and antibiotics, saw 35-40% average price increases, and a military face-off with China led to calls for the rejection of goods manufactured in the country.

After a hand-to-hand skirmish between Indian and Chinese soldiers on 15 June led to fatalities, the Indian government banned 59...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip